Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

This study has been completed.
Bausch & Lomb Incorporated
Information provided by:
Florida Eye Microsurgical Institute Identifier:
First received: August 21, 2007
Last updated: February 17, 2009
Last verified: February 2009

To compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of treatment for chronic dry eye disease

Condition Intervention Phase
Dry Eye Disease
Ocular Comfort
Drug: bromfenac
Drug: ketorolac
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients

Resource links provided by NLM:

Further study details as provided by Florida Eye Microsurgical Institute:

Primary Outcome Measures:
  • Ocular comfort [ Time Frame: six weeks ] [ Designated as safety issue: No ]

Enrollment: 42
Study Start Date: August 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Active treatment arm bromfenac 0.09% BID for 6 weeks
Drug: bromfenac
0.09%, BID, 6 weeks
Active Comparator: 2
ketorolac 0.4% BID for 6 weeks
Drug: ketorolac
0.4%, BID, 6 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be in general good health
  • Diagnosis of moderate to severe dry eye syndrome

Exclusion Criteria:

  • Patients who are unlikely to respond to cyclosporine ophthalmic emulsion therapy
  • Patients who are pregnant or nursing females
  • Unwilling to discontinue use of contact lenses during the run-in and duration of the study
  • Presence or history of any systemic or ocular disorder or condition that could possibly interfere with the interpretation of the study results in the study eye
  • Previous treatment failure on CSA 0.05% (Restasis)
  • Known hypersensitivity to any component of the study or procedural medications
  • Participation in any other clinical trial within 30 days prior to screening
  • Known contraindication to any study medication or any of their components.
  • Should not be taking any oral anti-histamines, beta blockers or diuretics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00520260

United States, Florida
Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Florida Eye Microsurgical Institute
Bausch & Lomb Incorporated
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute
  More Information

No publications provided

Responsible Party: Barry Schechter, MD, Florida Eye Microsurgical Institute Identifier: NCT00520260     History of Changes
Other Study ID Numbers: Sch012007
Study First Received: August 21, 2007
Last Updated: February 17, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Eye Diseases
Ketorolac Tromethamine
Analgesics, Non-Narcotic
Anti-Infective Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antifungal Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 27, 2014